Pulmatrix, Inc. (PULM)

NASDAQ: PULM · IEX Real-Time Price · USD
5.00
-0.30 (-5.63%)
May 18, 2022 11:39 AM EDT - Market open
Market Cap16.94M
Revenue (ttm)4.94M
Net Income (ttm)-24.24M
Shares Out3.39M
EPS (ttm)-8.63
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,165
Open5.23
Previous Close5.30
Day's Range5.00 - 5.23
52-Week Range4.83 - 23.40
Beta1.05
AnalystsBuy
Price Target10.20 (+104.0%)
Earnings DateMay 10, 2022

About PULM

Pulmatrix, Inc., a clinical stage biotechnology company, discovers and develops inhaled therapies to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company focuses on developing products based on its inhaled small particles easily respirable and emitted (iSPERSE) technology, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications. It engages in developing Pulmazole, an inhaled anti-fungal drug for the treatment of allergic bronchop...

IndustryPharmaceuticals
Founded2003
CEOTeofilo Raad
Employees24
Stock ExchangeNASDAQ
Ticker SymbolPULM
Full Company Profile

Financial Performance

In 2021, Pulmatrix's revenue was $5.17 million, a decrease of -59.09% compared to the previous year's $12.63 million. Losses were -$20.17 million, 4.47% more than in 2020.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for PULM stock is "Buy." The 12-month stock price forecast is 10.2, which is an increase of 104.00% from the latest price.

Price Target
$10.2
(104.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Pulmatrix Announces First Quarter 2022 Financial Results and Provides Corporate Update

Ends Q1 with $47.5 million in cash and cash equivalents; Extends cash runway into Q2 2024 LEXINGTON, Mass. , May 12, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutic...

6 days ago - PRNewsWire

Pulmatrix Announces Year-End and Q4 Financial 2021 Results and Provides Corporate Update

LEXINGTON, Mass. , March 29, 2022  /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non...

1 month ago - PRNewsWire

Pulmatrix's COPD Candidate Shows Early Safety, Preliminary Pharmacokinetic Results

Pulmatrix Inc (NASDAQ: PULM) announced topline results of its recently completed Phase 1b clinical study of PUR1800 in patients with stable Chronic Obstructive Pulmonary Disease (COPD). PUR1800 is a nar...

1 month ago - Benzinga

Pulmatrix Announces Positive Top-Line Data Evaluating PUR1800 in Patients with Stable COPD

LEXINGTON, Mass. , March 21, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

1 month ago - PRNewsWire

Pulmatrix Regains Compliance With Nasdaq Listing Requirements

LEXINGTON, Mass., March 17, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

2 months ago - PRNewsWire

PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?

As Pulmatrix executes a reverse stock split, shares of the tiny pharmaceutical company appear to be defying gravity. The post PULM Stock Alert: Is Pulmatrix Really Soaring More Than 1,800% Today?

2 months ago - InvestorPlace

Pulmatrix Announces Expansion of Executive Leadership Team to Progress Clinical Pipeline

LEXINGTON, Mass., March 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...

2 months ago - PRNewsWire

Pulmatrix, Inc. Announces 1-for-20 Reverse Stock Split

LEXINGTON, Mass. , Feb. 24, 2022 /PRNewswire/ -- Pulmatrix, Inc. ("Pulmatrix" or the "Company") (NASDAQ: PULM) a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...

2 months ago - PRNewsWire

Pulmatrix Issues Letter to Stockholders

LEXINGTON, Mass., Feb. 1, 2022 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...

3 months ago - PRNewsWire

Pulmatrix Announces Closing of $6.75 Million Registered Direct Offering

LEXINGTON, Mass., Dec. 17, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...

5 months ago - PRNewsWire

Pulmatrix Announces $6.75 Million Registered Direct Offering

LEXINGTON, Mass., Dec. 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (Nasdaq: PULM) ("Pulmatrix" or the "Company"), a clinical stage biopharmaceutical company developing innovative inhaled therapies to addre...

5 months ago - PRNewsWire

Pulmatrix, Inc. (PULM) Reports Q3 Loss, Misses Revenue Estimates

Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of -28.57% and -56.88%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Pulmatrix Reports Third Quarter 2021 Financial Results and Provides Business Update

LEXINGTON, Mass., Nov. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...

6 months ago - PRNewsWire

Pulmatrix Announces Resolution of Contract Dispute with Cipla

LEXINGTON, Mass., Nov. 9, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...

6 months ago - PRNewsWire

Pulmatrix, Inc. (PULM) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Bet on Rising P/E Investing With These Top 5 Stocks

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach.

Other symbols:CLVSLZBSTKLTPR
7 months ago - Zacks Investment Research

Pulmatrix, Inc. (PULM) Reports Q2 Loss, Tops Revenue Estimates

Pulmatrix, Inc. (PULM) delivered earnings and revenue surprises of 22.22% and 47.32%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

9 months ago - Zacks Investment Research

Pulmatrix Reports Second Quarter 2021 Financial Results and Provides Business Update

LEXINGTON, Mass., Aug. 10, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pu...

9 months ago - PRNewsWire

Earnings Preview: Pulmatrix, Inc. (PULM) Q2 Earnings Expected to Decline

Pulmatrix, Inc. (PULM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

Pulmatrix appoints Director Anand Varadan

LEXINGTON, Mass., July 27, 2021 /PRNewswire/ --  Pulmatrix, Inc.  (NASDAQ: PULM), a clinical-stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-...

9 months ago - PRNewsWire

Pulmatrix Reports First Quarter 2021 Financial Results and Provides Business Update

LEXINGTON, Mass., May 11, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-pul...

1 year ago - PRNewsWire

Pulmatrix Hosting Key Opinion Webinar on PUR3100 (Orally Inhaled DHE) Therapy for the Treatment of Acute Migraine

LEXINGTON, Mass., April 15, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

1 year ago - PRNewsWire

Corrected: Pulmatrix to Regain Full Rights to PUR1800 and Narrow Spectrum Kinase Inhibitor Portfolio

LEXINGTON, Mass., April 12, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), is re-issuing this press release solely to correct inadvertent typographical errors under the heading "Updated PUR1800 Pr...

1 year ago - PRNewsWire

Pulmatrix Reports 2020 Financial Results and Provides Business Update

LEXINGTON, Mass., March 23, 2021 /PRNewswire/ -- Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary and non-p...

1 year ago - PRNewsWire